Abstract
Introduction
An estimated 429,800 new cases of bladder cancer (BC) are diagnosed worldwide annually and almost 165,000 patients succumb to it [1, 2] . Approximately 75% of these patients, in Western countries have nonmuscle-invasive BC (NMIBC) at diagnosis [3] . Highgrade T1 (T1 HG/G3) is the NMIBC subtype with the highest risk of disease recurrence and progression [4] . The standard treatment of all T1 HG/G3 considered for bladder preservation is a re-transurethral resection (TUR), if NMIBC or T0 is identified on re-TUR then adjuvant intravesical Bacilus Calmette-Guerin (BCG) therapy with maintenance is often the therapy of choice [3, 5, 6] . However, up to 40% of patients with initial T1 HG/G3 eventually fail intravesical therapy with BCG within 5 years [7] .
Because of this high rate of disease progression to MIBC and the differentially worse prognosis of patients who experience disease progression compared to those presenting with MIBC, there has been intense research to identify T1 HG/G3 patients who are likely to fail BCG therapy and may therefore possibly benefit from intensified therapy such as early radical cystectomy (RC) [8] [9] [10] [11] [12] [13] . While, the American Urological Association guidelines suggest to offer an initial RC to patients with persistent T1 HG/G3 on re-TUR, the European Association of Urology (EAU) guidelines does not give specific recommendations [14] . Indeed, the presence of T1 on re-TUR after the initial TUR showing T1 HG/G3 confers worse survival in singlecenter or multicenter heterogeneous datasets. These studies are impacted by the negative effects of variable and sometimes older BCG therapy schemes among other design limitations [15, 16] . Persistent disease after initial T1 HG/G3 BC is indeed in approximately 33-55% of patients [15] [16] [17] , supporting the recommendation for re-TUR in all patients with T1 HG/G3 [3, 5] . But, in a large multi-institutional cohort of 2451 patients with T1 HG/G3 tumors treated with BCG, a second resection (n = 935) improved recurrence-free survival (RFS), progression-free survival (PFS), overall survival (OS), and cancer-specific survival (CSS) only in patients without muscle in the specimen in the initial resection [15] .
The aim of this multicenter study was to investigate and validate the prognostic impact of residual T1 HG/G3 tumors at re-TUR in a large multi-institutional cohort of patients who had T1 HG/G3 NMIBC on initial TUR and who were treated with intravesical BCG therapy according to guidelines.
Patients and Methods

Patient Selection and Data Collection
After an institutional-review-board approval in each institution, with all participating sites providing institutional data sharing agreements prior to the initiation of the study, a total of 1,155 patients with initial G3/HGT1 were treated between January 1, 2002 and December 31, 2012 at 13 academic institutions. The inclusion criteria were re-TUR within 4-6 weeks followed by intravesical BCG therapy with maintenance, generally according to the EAU guidelines at the time. Patients treated with intravesical chemotherapy were excluded (109 patients). Demographical, clinical, pathological, and outcomes data were collected and entered in a computerized database. Data integrity, completeness, and quality were ensured through internal and external revisions. Management and Follow-Up All patients had a standard TUR with curative intent followed by a re-TUR at 4-6 weeks following the initial TUR [3] . Informed consent was obtained from each patient. Complete resection of all papillary tumors was a condition for BCG therapy in concordance with the EAU guidelines. Re-TUR generally included a fractioned resection of all visible lesions, depth resection of base and borders of previous resection area, and biopsy of any abnormal mucosal area. Re-TUR was usually performed by the same urologist who performed the first TUR [18] . Pathological evaluation was carried out according to the TNM system of Union for International Cancer Control and to the 1973 World Health Organization grading classification [19] . Patients with NMIBC on re-TUR and those with no residual tumor received an induction 6 weeks course of intravesical BCG followed by standard maintenance scheme, which consisted of intravesical BCG -standard dose -every week for 3 weeks given at 3, 6, 12, 18, 24, 30, and 36 months from initiation of therapy [20] . Only 303 (29%) patients completed the treatment protocol as planned [21] . All patients were generally followed with cystoscopy and voiding urine cytology every 3-4 months for the first and second year, every 6 months for the third and fourth year, and annually thereafter. Diagnostic imaging of the upper tract was performed at least annually or when clinically indicated. Recurrence was defined as any tumor on follow-up and progression as MIBC on follow-up. Patients with muscle invasive disease on re-TUR and those who failed BCG underwent RC [3] .
Endpoints were time to RFS, PFS, OS, and CSS. The cause of death was determined by the treating physician, based on chart review corroborated by death certificates when possible [22] .
Statistical Analysis
We divided patients into 2 groups according to re-TUR results: pT0 or NMIBC other than T1 HG/G3 (Group A) and T1 HG/G3 (Group B) on re-TUR. Associations of T1 HG/G3 on re-TUR with categorical variables were assessed using χ 2 tests; differences in continuous variables were analyzed using Mann-Whitney U test. Univariable and multivariable logistic regression analyses were done to identify predictors of T1 HG/G3 on re-TUR. Kaplan-Meier method was used to estimate RFS, PFS, OS, and CSS; log-rank tests were applied for pair-wise comparison of survival. Univariable and multivariable Cox regression models addressed associations with RFS, PFS, OS, and CSS adjusting for the effects of standard clinicopathologic features. All p values were 2-sided, and statistical significance was defined as a p < 0.05. Statistical analyses were performed using Stata 14.0 statistical software (Stata Corp., College Station, TX, USA).
Results
Association of T1 HG/G3 on Re-TUR with Clinical and Pathologic Characteristics
From a total of 1046 patients with T1 HG/G3 on the initial TUR 257 (24.6%) had residual T1 HG/G3 on re-TUR. Residual T1 HG/G3 was associated with the presence of concomitant carcinoma in situ (CIS), multiple and large tumors (> 3 cm) on the initial TUR (p ≤ 0.001; p = 0.01; p = 0.03, respectively). We did not find an association with age, gender, and smoking status (Table 1) . On univariable analyses, current smoking status (OR 1.44, p = 0.03), tumor size (OR 1.38, p = 0.03), tumor multifocality (OR 1.44, p = 0.01), and concomitant CIS (OR 2.05, p < 0.001) were all associated with T1 HG/G3 on re-TUR. On multivariable analysis, tumor multifocality (OR 1.36, p = 0.03) and concomitant CIS (OR 2.01, p = 0.001) remained significantly associated with T1 HG/G3 on re-TUR ( Table 2) . (Fig. 1a, b) . T1 HG/G3 at re-TUR was associated with worse RFS (hazard ratio [HR] 1.72, CI 1.46-2.03, p < 0.001) and PFS (HR 1.78, CI 1.4-2.26, p < 0.001) on univariable Cox regression analyses. When adjusted for the effects of standard clinical and pathologic features from the initial TUR, residual T1 HG/G3 retained its significant association with both RFS (HR 1.63, CI 1.38-1.93, p < 0.001) and PFS (HR 1.56, CI 1.22-1.98, p < 0.001). Addition of this information from the re-TUR to a model that included the features of the initial TUR improved C-Index of the later by 4.1% for prediction disease recurrence and 2.3% for disease progression (Table 3) . (Fig. 2a, b) . T1 HG/G3 on re-TUR was associated with OS (HR 1.93, CI 1.39-2.68, p < 0.001) and CSS (HR 2.11, CI 1.34-3.32, p < 0.001) on univariable Cox regression analyses. When adjusted for the effects of clinical and pathologic features from the initial TUR, T1 HG/G3 on re-TUR retained its statistical significant association with both OS (HR 1.81, CI 1.29-2.54, p = 0.001) and CSS (HR 1.82, CI 1.14-2.92, p = 0.01). Addition of T1 HG/G3 on re-TUR to a base model including initial TUR information improved the C-Index of the later by 1.5% for OS and by 1.9% for CSS (Table 4) . 
Association of T1 HG/G3 on re-TUR with Disease Recurrence and Progression
Association of T1 HG/G3 on re-TUR with Overall and CSS
Discussion
We found that 24.6% of patients with initial T1 HG/G3 had residual T1 HG/G3. This is in agreement with the previous literature. For example, Herr et al. [16] reported that 23% patients with T1 G3 at initial TUR had residual T1 G3 on re-TUR. Similarly, Vasdev et al. [23] found that 23.8% patients with T1G3 on TUR had residual T1 G3 on re-TUR. On the other hand, Gontero et al. [15] reported even a higher rate (30.9%) in a multicenter international study. Recently, a prospective study that included 198 patients with T1 HG/G3 also showed that 1/4 of patients have T1 HG/G3 on re-TUR; they also demonstrated that extent of T1 invasion did not eliminate the need for re-TUR [24] .
In our study, T1 HG/G3 on re-TUR was associated with adverse pathological features such as multifocality, larger tumor size, and concomitant CIS. Of note, multifocality and the presence of concomitant CIS were both independent predictors of residual T1 HG/G3 on re-TUR. This is in accordance with reports from smaller studies in which both were found to be predictors for residual T1 HG/G3 [12, [25] [26] [27] [28] . While, it is important to identify patients who are likely to harbor residual T1 HG/G3 on re-TUR, this matters only if T1 on re-TUR impacts progression.
We found that residual T1 HG/G3 for T1 HG/G3 confers worse oncologic outcomes. Previous studies already reported higher recurrence (45% [29] to 84% [30] ) and progression rates (16% [27] to 76% -includes 
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BCG, Bacillus Calmette-Guérin; OS, overall survival; CSS, cancer-specific survival; HR, hazard ratio; CIS, carcinoma in situ; HG, high grade; TUR, transurethral resection of bladder tumor. patients with stage and grade progression) [16] in patients with T1 HG/G3 on re-TUR compared to the other subgroups of NMIBC. Herr et al. [16] reported that 90% of T1G3 patients experienced disease recurrence and 76% had disease progression (mean follow-up of 78 months). These rates are lower than those in our study, probably compared due to longer follow-up and differences in the BCG schedule scheme as only 138 (24%) patients received 2 or more than 2 BCG courses. In a prospective randomized study comparing BCG with epirubicin and interferon-α2b in patients with T1 residual tumor on re-TUR was significantly associated with an increased risk of recurrence as well as treatment failure [31] . Various mono-center studies confirmed that residual tumor on re-TUR is a harbinger for disease recurrence and progression compared to pT0 on re-TUR [32, 33] . Disease progression of NMIBC is usually associated with worse survival compared to the novo MIBC [34] . We found that residual T1 HG/G3 on re-TUR for T1 HG/G3 increased the accuracy of standard models for predicting all 3 factors -disease recurrence, progression, and survival. While, residual T1 HG/G3 was associated with a 63% increased risk of disease recurrence and a 56% increased risk of disease progression, it also increased the risk of all-cause mortality by 81% and that of CSS by 82%. Similarly, Kamiya et al. [27] showed, in their multicenter study, that T1 on re-TUR negatively impacted CSS in pa- tients with primary HG NMIBC. This information should be taken into consideration for the clinical decision regarding early RC, as it has previously been shown that patients with de novo T2 have more favorable longterm disease-free survival compared to patients who experienced disease progression [35, 36] . Indeed, many patients at time of early RC are upstaged (pT2 or greater, 41%) and 12.7% have even lymph node metastases [36, 37] . Despite this being the largest study to our knowledge investigating the prognostic value of residual T1 HG/G3 on re-TUR in patients with primary T1 HG/G3 treated with maintenance BCG, some limitations should be considered. First, its retrospective nature carries some intrinsic limitations. Second, some other factors could have been considered because they have been recognized as possible prognostic factors in T1 HG/G3 patients such as markers of systemic inflammation response [38, 39] , lymphovascular invasion [40] , and variant histology [41] . Third, due to the multi-center design, there is heterogeneity, as multiple surgeons and pathologists were implicated; however, in all centers, slides were reviewed by dedicated uro-pathologists, who reported that a complete first TUR and time for RC was only in case of progression to MIBC. While, with larger follow-up, the effect of T1 HG/G3 on re-TUR may change, its prognostic value would, however, remain the same.
Conclusion
Residual T1 HG/G3 tumor at re-TUR confers a statistically and prognostically worse prognosis in patients with primary T1 HG/G3 treated with maintenance BCG. Multifocality and concomitant CIS on primary TUR predict the risk of finding T1 HG/G3 on re-TUR. Patients with residual T1 HG/G3 for primary T1 HG/G3 are very likely to fail BCG therapy alone and should be considered for intensified therapy such as early RC or novel trials of immune checkpoint-inhibitors or device-assisted intravesical therapy.
